Solid Biosciences Inc. reported a net loss of $42.6 million for the fourth quarter of 2025, a sharp increase from the $1.12 million loss reported a year earlier. The full‑year loss rose to $174.3 million, reflecting the company’s continued investment in research and development and a one‑time restructuring charge. Revenue remained at $0.00, consistent with the company’s pre‑revenue status.
Operating expenses for the quarter totaled $49.4 million, driven by $38.1 million in research and development costs and $11.3 million in general and administrative expenses. These figures are substantially higher than the $3.90 million expense reported in the original article and illustrate the heavy capital outlay required to advance the company’s gene‑therapy pipeline.
The company reiterated its 2026 guidance, projecting a cash burn of approximately $34 million per quarter and a runway extending into the first half of 2028. The guidance reflects confidence that the $240 million private placement completed in March 2026 will strengthen the balance sheet and support ongoing clinical development.
Earnings per share for the quarter were $‑0.53, missing consensus estimates of $‑0.48. The miss is largely attributable to the elevated R&D and G&A expenses and the one‑time restructuring charge, which together amplified the loss relative to expectations.
Management emphasized the positive momentum in its pipeline: “We continue to build momentum across our portfolio, highlighted by updated interim INSPIRE DUCHENNE data presented at MDA, positive feedback from our FDA Type C meeting on the Phase 3 IMPACT DUCHENNE trial design for SGT‑003, the dosing of our first participant in the FALCON trial for SGT‑212 and the completion of an oversubscribed $240 million private placement.” “With multiple anticipated regulatory and clinical milestones ahead, we believe 2026 will be a transformational year for Solid.”
The market reacted positively, driven by the interim clinical data for SGT‑003 and the strong analyst upgrades that followed the earnings release.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.